D., Arsenault, B., Cuevas, A., Hu, F
In the STEP trials, semaglutide produced average weight loss of 1518% at the 2.4 mg maintenance dose, with approximately 80% of participants achieving clinically significant (5%) weight loss
Side effects are rare but can include mild digestive discomfort
What works perfectly for one person might need tweaking for another, especially as your body continues adapting to GLP-1 treatment
Pembrolizumab) * Targeted therapy (for BRAF mutations) * Chemotherapy (less common now) Prognosis * Depends on how early its detected * Thin, early melanomas very good survival * Late/metastatic disease poorer outcomes Prevention * Use sunscreen (SPF 30+) * Avoid midday sun * Wear protective clothing * Regular skin checks * Aggressive skin cancer from melanocytes * ABCDE rule helps early detection * Early surgical removal is curative To view or add a comment, sign in 40,015 followers